JOURNAL ARTICLE
[Endomyocardial disease as the first manifestation of hypereosinophilic syndrome].
Kardiologia Polska 2010 April
A case of hypereosinophilic syndrome (HES) initially manifesting as endomyocardial disease in a 21-year-old man is presented. The diagnosis of HES was made according to the Chusid's criteria. Myeloproliferative disorders were excluded and corticosteroid therapy with prednisone at a dose of 1 mg/kg/d was started immediately. After 30 days of continuous corticotherapy the patient recovered completely. His blood eosinophil count decreased from 8740 cells/microL (48.7%) to 30 cells/microL (0.3%). Then, prednisone was discontinued gradually. During 18-month follow-up the patient was free from cardiovascular symptoms and his complete blood count was normal. We also present the current state of knowledge on the cardiovascular complications of hypereosinophilic syndrome.
Full text links
Trending Papers
Management of heart failure in patients with kidney disease - updates from the 2021 ESC guidelines.Nephrology, Dialysis, Transplantation 2023 January 24
2023 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting: Carbohydrate-containing Clear Liquids with or without Protein, Chewing Gum, and Pediatric Fasting Duration-A Modular Update of the 2017 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting.Anesthesiology 2023 Februrary 2
Chronic Kidney Disease, Urinary Tract Infections and Antibiotic Nephrotoxicity: Are There Any Relationships?Medicina 2022 December 28
Guidelines to the Practice of Anesthesia: Revised Edition 2023.Canadian Journal of Anaesthesia 2023 January 24
How I Treat Multiple myeloma in the geriatric patient.Blood 2023 January 25
Management of Latent Tuberculosis Infection.JAMA 2023 January 20
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app